Skip to main content

Extracellular vesicles from mesenchymal stromal cells as new treatment for preeclampsia

Project Member(s): McClements, L.

Funding or Partner Organisation: NSW Cardiovascular Research Network (NSW CVRN Near Miss Grants)
NSW Cardiovascular Research Network (NSW CVRN Near Miss Grants)

Start year: 2022

Summary: The 2021 NHMRC Ideas grant I submitted as a CIA includes a multidisciplinary team of scientists, clinicians and biomedical engineers in women’s cardiovascular disease (CVD), which is an area of critical concern of CVD with unmet clinical need. Preeclampsia is the leading cause of mortality and morbidity in pregnancy and it is associated with increased risk of future cardiovascular and metabolic diseases for both the mothers and offspring. The only definite treatment for preeclampsia is the delivery of the baby (and the placenta), often preterm and with complications. Mesenchymal stem cells (MSC) are emerging as a promising treatment for preeclampsia based on a number of preclinical studies, however MSC-secreted extracellular vesicles (MSC-EVs) represent a more compelling treatment option as a cell-free therapy with safer profile and are more cost-effective. MSCs exert their reparative and regenerative therapeutic effects via EVs, which carry molecular cargo and cell organelles to target cells. In my NHMRC Ideas grant I propose to demonstrate therapeutic potential and identify comprehensive placental/cardiac and systemic mechanisms of MSC-EVs effects in the most reliable preclinical model of preeclampsia in rats, reduced uterine perfusion pressure (RUPP).

FOR Codes: Reproductive medicine, Regenerative medicine (incl. stem cells), Specific population health (excl. Indigenous health), Expanding knowledge in the biological sciences